KR960029314A - 사이클로스포린-a와 다른 면역억제제의 독성효과를 감소를 위한 l-카르니틴 및 알카노일 l-카르니틴 유도체의 용도 - Google Patents
사이클로스포린-a와 다른 면역억제제의 독성효과를 감소를 위한 l-카르니틴 및 알카노일 l-카르니틴 유도체의 용도 Download PDFInfo
- Publication number
- KR960029314A KR960029314A KR1019960001086A KR19960001086A KR960029314A KR 960029314 A KR960029314 A KR 960029314A KR 1019960001086 A KR1019960001086 A KR 1019960001086A KR 19960001086 A KR19960001086 A KR 19960001086A KR 960029314 A KR960029314 A KR 960029314A
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- alkanoyl
- pharmaceutically acceptable
- acceptable salt
- cyclosporin
- Prior art date
Links
- -1 alkanoyl L-carnitine derivatives Chemical class 0.000 title claims abstract 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract 4
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract 4
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract 4
- 229960001265 ciclosporin Drugs 0.000 title claims abstract 4
- 229940046781 other immunosuppressants in atc Drugs 0.000 title 1
- 231100000331 toxic Toxicity 0.000 title 1
- 230000002588 toxic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract 5
- 229940125721 immunosuppressive agent Drugs 0.000 claims abstract 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 3
- 229960002930 sirolimus Drugs 0.000 claims abstract 3
- 206010029155 Nephropathy toxic Diseases 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 230000007694 nephrotoxicity Effects 0.000 claims abstract 2
- 231100000417 nephrotoxicity Toxicity 0.000 claims abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229960004203 carnitine Drugs 0.000 claims 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002706 gusperimus Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/34—Preparation of optical isomers by separation of optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
본 발명은 L-카르니틴 또는 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도에 관한 것으로서, 더욱 상세하게는 사이클로스포린-A, 타크로리무스, 라파마이신 및 데옥시스페구아린과 같은 면역억제제 치료시 발생하는 신독(腎毒)과 혈관독(血管毒) 억제제에 유용한 L-카르니틴 또는 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 면역억제제 투여에 의해 야기되는 신독(腎毒) 및 혈관독(血管毒)을 억제하는 약물로서 유용한 L-카르니틴 또는 탄소원수 2~6의 직쇄 또는 측쇄의 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도.
- 제1항에 있어서, 상기 면역억제제는 사이클로스포린-A, 타크로리무스, 라파마이신 및 데옥시스페구아린 중에서 선택된 것임을 특징으로 하는 L-카르니틴 또는 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도.
- 제1항에 있어서, 사이 알카노일 L-카르니틴유도체는 아세틸, 프로피오닐, 부티릴, 발레릴 및 이소발레릴 L-카르니틴 중에서 선택된 것임을 특징으로 하는 L-카르니틴 또는 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도.
- 제1항 내지 제3항에서 선택된 하나의 항에 있어서, 상기 L-카르니틴 또는 알카노일 L-카르니틴의 약제학적 허용 가능한 염은 클로라이드, 브로마이드, 오로테이트, 엑시드 아스파테이트, 엑시드 시트레이트, 엑시드 포스페이트, 푸마레이트, 엑시드 푸마레이트, 락테이트, 말레에이트, 엑시드 말레에이트, 엑시드 옥살레이트, 엑시드 술페이트, 글루코스 포스페이트, 타르트레이트 및 엑시드 타르트레이트 중에서 선택된 것임을 특징으로 하는 L-카르니틴 또는 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염의 용도.
- L-카르니틴 또는 탄소원수 2~6의 직쇄 또는 측쇄의 알카노일 L-카르니틴 유도체 또는 이들의 약제학적 허용 가능한 염, 그리고 면역억제제를 유효성분으로 하고, 여기에 약제학적으로 허용가능한 부형제가 함유되어 있는 것임을 특징으로 하는 경구 투어용 또느 비경구 투여용 약제조성물.
- 제5항에 있어서, 상기 알카노일 L-카르니틴은 아세틸, 프로피오닐, 부티릴, 발레릴 및 소발레릴 L-카르니틴 중에서 선택된 것 또는 이들의 약제학적 허용 가능한 염이고, 상기 면역억제제는 사이클로스포린-A, 타크로리무스, 라파마이신 및 데옥시스페구아린 중에서 선택된 것임을 특징으로 하는 경구 투여용 또는 비경구 투여용 약제조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95RM000037A IT1277147B1 (it) | 1995-01-20 | 1995-01-20 | Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi. |
| ITRM95A000037 | 1995-01-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960029314A true KR960029314A (ko) | 1996-08-17 |
| KR100443730B1 KR100443730B1 (ko) | 2004-10-14 |
Family
ID=11402949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960001086A KR100443730B1 (ko) | 1995-01-20 | 1996-01-19 | 사이클로스포린-a와다른면역억제제의독성효과를감소를위한l-카르니틴및알카노일l-카르니틴유도체의용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5955424A (ko) |
| EP (1) | EP0722724B1 (ko) |
| JP (1) | JPH08231390A (ko) |
| KR (1) | KR100443730B1 (ko) |
| AT (1) | ATE177946T1 (ko) |
| CA (1) | CA2167456A1 (ko) |
| DE (1) | DE69508551T2 (ko) |
| DK (1) | DK0722724T3 (ko) |
| ES (1) | ES2130509T3 (ko) |
| GR (1) | GR3030545T3 (ko) |
| IT (1) | IT1277147B1 (ko) |
| TW (1) | TW445145B (ko) |
| ZA (1) | ZA96431B (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
| IT1306179B1 (it) | 1999-07-28 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale. |
| IT1316998B1 (it) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. |
| CA2424823A1 (en) * | 2000-10-12 | 2002-04-18 | Pharma Mar, S.A. | Treatment of cancers by aplidine in conjunction with a myoprotector |
| ITRM20010293A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore. |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| US20070087975A1 (en) * | 2005-10-17 | 2007-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
| CN102038671B (zh) * | 2010-06-29 | 2012-07-04 | 辽宁思百得医药科技有限公司 | 包含左卡尼汀和羟苯磺酸盐的药物组合物 |
| KR101760510B1 (ko) | 2014-12-18 | 2017-07-21 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
| WO2016099214A1 (ko) * | 2014-12-18 | 2016-06-23 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
| CN115469026B (zh) * | 2022-07-14 | 2023-10-20 | 中日友好医院(中日友好临床医学研究所) | 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195852B (it) * | 1986-07-04 | 1988-10-27 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati |
| JPH01213258A (ja) * | 1988-02-23 | 1989-08-28 | Kyowa Hakko Kogyo Co Ltd | カルニチンおよびカルニチンアミドの精製法 |
-
1995
- 1995-01-20 IT IT95RM000037A patent/IT1277147B1/it active IP Right Grant
- 1995-12-22 AT AT95120394T patent/ATE177946T1/de not_active IP Right Cessation
- 1995-12-22 DE DE69508551T patent/DE69508551T2/de not_active Expired - Fee Related
- 1995-12-22 EP EP95120394A patent/EP0722724B1/en not_active Expired - Lifetime
- 1995-12-22 ES ES95120394T patent/ES2130509T3/es not_active Expired - Lifetime
- 1995-12-22 DK DK95120394T patent/DK0722724T3/da active
- 1995-12-26 TW TW084113879A patent/TW445145B/zh not_active IP Right Cessation
-
1996
- 1996-01-03 US US08/580,993 patent/US5955424A/en not_active Expired - Fee Related
- 1996-01-17 CA CA002167456A patent/CA2167456A1/en not_active Abandoned
- 1996-01-19 ZA ZA96431A patent/ZA96431B/xx unknown
- 1996-01-19 KR KR1019960001086A patent/KR100443730B1/ko not_active IP Right Cessation
- 1996-01-22 JP JP8008347A patent/JPH08231390A/ja active Pending
-
1997
- 1997-09-08 US US08/925,485 patent/US5958941A/en not_active Expired - Fee Related
-
1999
- 1999-06-16 GR GR990401622T patent/GR3030545T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2167456A1 (en) | 1996-07-21 |
| EP0722724A1 (en) | 1996-07-24 |
| US5955424A (en) | 1999-09-21 |
| ITRM950037A0 (it) | 1995-01-20 |
| TW445145B (en) | 2001-07-11 |
| DE69508551D1 (de) | 1999-04-29 |
| JPH08231390A (ja) | 1996-09-10 |
| KR100443730B1 (ko) | 2004-10-14 |
| EP0722724B1 (en) | 1999-03-24 |
| IT1277147B1 (it) | 1997-11-04 |
| US5958941A (en) | 1999-09-28 |
| ATE177946T1 (de) | 1999-04-15 |
| ES2130509T3 (es) | 1999-07-01 |
| DK0722724T3 (da) | 1999-10-11 |
| GR3030545T3 (en) | 1999-10-29 |
| ITRM950037A1 (it) | 1996-07-20 |
| ZA96431B (en) | 1996-08-08 |
| DE69508551T2 (de) | 1999-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960029314A (ko) | 사이클로스포린-a와 다른 면역억제제의 독성효과를 감소를 위한 l-카르니틴 및 알카노일 l-카르니틴 유도체의 용도 | |
| US5266594A (en) | Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity | |
| JP2002521428A5 (ko) | ||
| KR970061865A (ko) | 신규 치환된 구아니딘 유도체, 그의 제조방법, 및 그의 약제학적 용도 | |
| CA2468133A1 (en) | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | |
| ATE194846T1 (de) | Zyklische antimikrobielle peptide und deren herstellung | |
| Thomas et al. | Vascular activity of polycations and basic amino acids: L-arginine does not specifically elicit endothelium-dependent relaxation | |
| Chatterjee et al. | Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin | |
| EP0514359A3 (en) | Alkanoyl l-carnitine amides with aminoacids and pharmaceutical compositions containing same, for promoting regeneration of the nervous tissue, inhibiting neuronal degeneration, enhancing the processes of learning and memory, and for the treatment of coma | |
| CA2229228C (en) | Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine | |
| KR950000141A (ko) | 피부병 치료용 약제조성물 제조를 위한 방향족산을 함유한 l- 카르니틴 o-에스테르의 용도 | |
| KR940006576A (ko) | 에이즈 및 에이즈 관련 증후군 환자 및 무증후성 hiv혈청양성 환자치료를 위한 l-카르니틴 및 아실 l-카르니틴의 용도 | |
| CA2256391A1 (en) | Anticoagulant peptidyl-arginine aldehyde derivatives | |
| IE51711B1 (en) | Carnitine derivatives | |
| JP3247695B2 (ja) | エタノール摂取を妨げるチオカルバメートスルホキシド組成物 | |
| ZA93161B (en) | Esters of acyl carnitines with long-chain alpihatic alcohols and pharmaceutical compositions containing same having antibacterial activity | |
| AU2001241031B8 (en) | Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents | |
| KR930007442A (ko) | L-카르니틴 및 아실 l-카르니틴의 원발성 정충무력 과소증 치료에의 용도 | |
| KR920703067A (ko) | 말초 신경질환 및 뇌질환 치료용 L-α-글리세로포르포릴-D-미오-이노시톨 | |
| KR930001906A (ko) | 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도 | |
| SK12402002A3 (sk) | Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10 | |
| US4812482A (en) | Application of α-[[(2-hydroxy-1, 1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride (EL-508) as a drug with antiinflammatory action | |
| AU2001241031A1 (en) | Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents | |
| KR920016091A (ko) | 완전 비경구 영양법에 의해 유발되는 간내 담즙분비정지의 치료에 있어서 s-아데노실-l-메티오닌의 용도 | |
| Li et al. | Effect of Vehicles and Penetration Enhancers on the In Vitro and In Vivo Percutaneous Absorption of Methotrexate and Edatrexate Through Hairless Mouse Skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |